Do analysts rate LUCD or ATYR?

Lucid Diagnostics currently has a consensus price target of $4.19, indicating a potential upside of 434.87%. Given Lucid Diagnostics' stronger consensus rating and higher possible upside, analysts plainly believe Lucid Diagnostics is more favorable than aTyr Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lucid Diagnostics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 aTyr Pharma 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.25

Do analysts prefer NGEN or ATYR?

NervGen Pharma currently has a consensus target price of $14.00, suggesting a potential upside of 542.20%. Given NervGen Pharma's stronger consensus rating and higher possible upside, research analysts clearly believe NervGen Pharma is more favorable than aTyr Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NervGen Pharma 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 2.83 aTyr Pharma 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.25

Is NGEN or ATYR more profitable?

aTyr Pharma's return on equity of -95.89% beat NervGen Pharma's return on equity. Company Net Margins Return on Equity Return on Assets NervGen Pharma N/A -1,259.82% -199.79% aTyr Pharma N/A -95.89% -69.67%

Does the media prefer NGEN or ATYR?

In the previous week, NervGen Pharma and NervGen Pharma both had 2 articles in the media. NervGen Pharma's average media sentiment score of 0.94 equaled aTyr Pharma'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NervGen Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive aTyr Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ATYR or KRRO?

Korro Bio has a consensus target price of $16.71, indicating a potential upside of 21.03%. Given Korro Bio's stronger consensus rating and higher possible upside, analysts clearly believe Korro Bio is more favorable than aTyr Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score aTyr Pharma 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.25 Korro Bio 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 3 Strong Buy rating(s) 2.92

Which has preferable earnings & valuation, ATYR or KRRO?

aTyr Pharma has higher earnings, but lower revenue than Korro Bio. Korro Bio is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio aTyr Pharma $190K 221.89 -$74.12M -$0.62 N/A Korro Bio $6.39M 31.83 -$117.26M -$10.00 N/A

Is ATYR or KRRO more profitable?

aTyr Pharma has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. aTyr Pharma's return on equity of -95.89% beat Korro Bio's return on equity. Company Net Margins Return on Equity Return on Assets aTyr Pharma N/A -95.89% -69.67% Korro Bio -1,834.48% -114.26% -68.57%

Does the media prefer ATYR or KRRO?

In the previous week, Korro Bio had 5 more articles in the media than aTyr Pharma. MarketBeat recorded 7 mentions for Korro Bio and 2 mentions for aTyr Pharma. aTyr Pharma's average media sentiment score of 0.94 beat Korro Bio's score of 0.58 indicating that aTyr Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment aTyr Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Korro Bio 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ATYR or MOLN?

Molecular Partners has a consensus price target of $8.38, indicating a potential upside of 100.84%. Given Molecular Partners' higher probable upside, analysts clearly believe Molecular Partners is more favorable than aTyr Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score aTyr Pharma 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.25 Molecular Partners 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is ATYR or MOLN more profitable?

Molecular Partners' return on equity of -68.36% beat aTyr Pharma's return on equity. Company Net Margins Return on Equity Return on Assets aTyr Pharma N/A -95.89% -69.67% Molecular Partners N/A -68.36% -54.82%

Do analysts rate ADCT or ATYR?

ADC Therapeutics currently has a consensus price target of $5.00, indicating a potential upside of 369.48%. Given ADC Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe ADC Therapeutics is more favorable than aTyr Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ADC Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 aTyr Pharma 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.25

Does the media favor ADCT or ATYR?

In the previous week, ADC Therapeutics had 1 more articles in the media than aTyr Pharma. MarketBeat recorded 3 mentions for ADC Therapeutics and 2 mentions for aTyr Pharma. aTyr Pharma's average media sentiment score of 0.94 beat ADC Therapeutics' score of 0.56 indicating that aTyr Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADC Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive aTyr Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

aTyr Pharma (ATYR) Competitors

$0.43 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$0.43 +0.00 (+0.05%)

As of 09/11/2026 07:59 PM Eastern

Compare

ATYR vs. LUCD, NGEN, KRRO, MOLN, and ADCT

Should you buy aTyr Pharma stock or one of its competitors? aTyr Pharma's main competitors and comparable companies include Lucid Diagnostics (LUCD), NervGen Pharma (NGEN), Korro Bio (KRRO), Molecular Partners (MOLN), and ADC Therapeutics (ADCT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does aTyr Pharma compare to Lucid Diagnostics?

Lucid Diagnostics (NASDAQ:LUCD) and aTyr Pharma (NASDAQ:ATYR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

Lucid Diagnostics has higher revenue and earnings than aTyr Pharma. Lucid Diagnostics is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$4.71M	33.78	-$58.01M	-$0.47	N/A
aTyr Pharma	$190K	221.89	-$74.12M	-$0.62	N/A

In the previous week, aTyr Pharma had 1 more articles in the media than Lucid Diagnostics. MarketBeat recorded 2 mentions for aTyr Pharma and 1 mentions for Lucid Diagnostics. Lucid Diagnostics' average media sentiment score of 1.89 beat aTyr Pharma's score of 0.94 indicating that Lucid Diagnostics is being referred to more favorably in the media.

Company	Overall Sentiment
Lucid Diagnostics	Very Positive
aTyr Pharma	Positive

74.0% of Lucid Diagnostics shares are owned by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are owned by institutional investors. 6.9% of Lucid Diagnostics shares are owned by company insiders. Comparatively, 5.8% of aTyr Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

aTyr Pharma has a net margin of 0.00% compared to Lucid Diagnostics' net margin of -959.76%. Lucid Diagnostics' return on equity of 0.00% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-959.76%	N/A	-119.57%
aTyr Pharma	N/A	-95.89%	-69.67%

Lucid Diagnostics currently has a consensus price target of $4.19, indicating a potential upside of 434.87%. Given Lucid Diagnostics' stronger consensus rating and higher possible upside, analysts plainly believe Lucid Diagnostics is more favorable than aTyr Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25

Lucid Diagnostics has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market. Comparatively, aTyr Pharma has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market.

Summary

Lucid Diagnostics beats aTyr Pharma on 11 of the 17 factors compared between the two stocks.

How does aTyr Pharma compare to NervGen Pharma?

NervGen Pharma (NASDAQ:NGEN) and aTyr Pharma (NASDAQ:ATYR) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

NervGen Pharma currently has a consensus target price of $14.00, suggesting a potential upside of 542.20%. Given NervGen Pharma's stronger consensus rating and higher possible upside, research analysts clearly believe NervGen Pharma is more favorable than aTyr Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25

aTyr Pharma's return on equity of -95.89% beat NervGen Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NervGen Pharma	N/A	-1,259.82%	-199.79%
aTyr Pharma	N/A	-95.89%	-69.67%

NervGen Pharma has higher earnings, but lower revenue than aTyr Pharma. NervGen Pharma is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NervGen Pharma	N/A	N/A	-$31.58M	-$0.46	N/A
aTyr Pharma	$190K	221.89	-$74.12M	-$0.62	N/A

In the previous week, NervGen Pharma and NervGen Pharma both had 2 articles in the media. NervGen Pharma's average media sentiment score of 0.94 equaled aTyr Pharma'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NervGen Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
aTyr Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

61.7% of aTyr Pharma shares are owned by institutional investors. 5.8% of aTyr Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

NervGen Pharma and aTyr Pharma tied by winning 6 of the 12 factors compared between the two stocks.

How does aTyr Pharma compare to Korro Bio?

aTyr Pharma (NASDAQ:ATYR) and Korro Bio (NASDAQ:KRRO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

In the previous week, Korro Bio had 5 more articles in the media than aTyr Pharma. MarketBeat recorded 7 mentions for Korro Bio and 2 mentions for aTyr Pharma. aTyr Pharma's average media sentiment score of 0.94 beat Korro Bio's score of 0.58 indicating that aTyr Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
aTyr Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Korro Bio	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

aTyr Pharma has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market. Comparatively, Korro Bio has a beta of 3.09, meaning that its share price is 209% more volatile than the broader market.

aTyr Pharma has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. aTyr Pharma's return on equity of -95.89% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
aTyr Pharma	N/A	-95.89%	-69.67%
Korro Bio	-1,834.48%	-114.26%	-68.57%

aTyr Pharma has higher earnings, but lower revenue than Korro Bio. Korro Bio is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
aTyr Pharma	$190K	221.89	-$74.12M	-$0.62	N/A
Korro Bio	$6.39M	31.83	-$117.26M	-$10.00	N/A

61.7% of aTyr Pharma shares are owned by institutional investors. Comparatively, 13.2% of Korro Bio shares are owned by institutional investors. 5.8% of aTyr Pharma shares are owned by company insiders. Comparatively, 4.8% of Korro Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Korro Bio has a consensus target price of $16.71, indicating a potential upside of 21.03%. Given Korro Bio's stronger consensus rating and higher possible upside, analysts clearly believe Korro Bio is more favorable than aTyr Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92

Summary

aTyr Pharma beats Korro Bio on 9 of the 17 factors compared between the two stocks.

How does aTyr Pharma compare to Molecular Partners?

aTyr Pharma (NASDAQ:ATYR) and Molecular Partners (NASDAQ:MOLN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

Molecular Partners has a consensus price target of $8.38, indicating a potential upside of 100.84%. Given Molecular Partners' higher probable upside, analysts clearly believe Molecular Partners is more favorable than aTyr Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

aTyr Pharma has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market. Comparatively, Molecular Partners has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market.

Molecular Partners' return on equity of -68.36% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
aTyr Pharma	N/A	-95.89%	-69.67%
Molecular Partners	N/A	-68.36%	-54.82%

In the previous week, aTyr Pharma had 1 more articles in the media than Molecular Partners. MarketBeat recorded 2 mentions for aTyr Pharma and 1 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 1.87 beat aTyr Pharma's score of 0.94 indicating that Molecular Partners is being referred to more favorably in the news media.

Company	Overall Sentiment
aTyr Pharma	Positive
Molecular Partners	Very Positive

aTyr Pharma has higher earnings, but lower revenue than Molecular Partners. Molecular Partners is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
aTyr Pharma	$190K	221.89	-$74.12M	-$0.62	N/A
Molecular Partners	$5.65M	29.80	-$74.41M	-$1.71	N/A

61.7% of aTyr Pharma shares are held by institutional investors. Comparatively, 26.6% of Molecular Partners shares are held by institutional investors. 5.8% of aTyr Pharma shares are held by company insiders. Comparatively, 5.9% of Molecular Partners shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Molecular Partners beats aTyr Pharma on 8 of the 15 factors compared between the two stocks.

How does aTyr Pharma compare to ADC Therapeutics?

ADC Therapeutics (NYSE:ADCT) and aTyr Pharma (NASDAQ:ATYR) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

ADC Therapeutics currently has a consensus price target of $5.00, indicating a potential upside of 369.48%. Given ADC Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe ADC Therapeutics is more favorable than aTyr Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25

aTyr Pharma has a net margin of 0.00% compared to ADC Therapeutics' net margin of -121.77%. ADC Therapeutics' return on equity of 0.00% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADC Therapeutics	-121.77%	N/A	-32.74%
aTyr Pharma	N/A	-95.89%	-69.67%

In the previous week, ADC Therapeutics had 1 more articles in the media than aTyr Pharma. MarketBeat recorded 3 mentions for ADC Therapeutics and 2 mentions for aTyr Pharma. aTyr Pharma's average media sentiment score of 0.94 beat ADC Therapeutics' score of 0.56 indicating that aTyr Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADC Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
aTyr Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

41.1% of ADC Therapeutics shares are owned by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are owned by institutional investors. 5.1% of ADC Therapeutics shares are owned by insiders. Comparatively, 5.8% of aTyr Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

aTyr Pharma has lower revenue, but higher earnings than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADC Therapeutics	$81.36M	1.67	-$142.62M	-$0.66	N/A
aTyr Pharma	$190K	221.89	-$74.12M	-$0.62	N/A

ADC Therapeutics has a beta of 1.84, suggesting that its share price is 84% more volatile than the broader market. Comparatively, aTyr Pharma has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market.

Summary

aTyr Pharma beats ADC Therapeutics on 9 of the 17 factors compared between the two stocks.

Get aTyr Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATYR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATYR vs. The Competition

Export

Metric	aTyr Pharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$42.16M	$3.85B	$7.15B	$12.84B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-0.69	14.25	275.25	25.35
Price / Sales	221.89	1,401.46	641.16	90.72
Price / Cash	N/A	43.64	28.42	34.96
Price / Book	0.62	15.35	10.42	6.21
Net Income	-$74.12M	-$22.86M	$3.50B	$358.54M
7 Day Performance	-13.57%	-4.34%	-3.27%	-2.35%
1 Month Performance	-23.11%	-0.62%	-0.82%	-3.37%
1 Year Performance	-92.87%	40.81%	23.56%	8.81%

aTyr Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATYR aTyr Pharma	0.6015 of 5 stars	$0.43 flat	N/A	-92.9%	$42.16M	$190K	N/A	53	High Trading Volume
LUCD Lucid Diagnostics	2.997 of 5 stars	$0.94 flat	$4.19 +345.7%	-24.0%	$190.95M	$4.71M	N/A	70	Positive News Gap Up
NGEN NervGen Pharma	2.1069 of 5 stars	$2.33 flat	$14.00 +500.9%	N/A	$187.87M	N/A	N/A	N/A
KRRO Korro Bio	2.372 of 5 stars	$12.24 flat	$16.71 +36.6%	-55.1%	$180.24M	$6.39M	N/A	70	Positive News Gap Down
MOLN Molecular Partners	2.6167 of 5 stars	$4.29 -1.5%	$8.38 +95.4%	+13.4%	$175.63M	$5.65M	N/A	180

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATYR) was last updated on 9/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

aTyr Pharma (ATYR) Competitors

ATYR vs. LUCD, NGEN, KRRO, MOLN, and ADCT

How does aTyr Pharma compare to Lucid Diagnostics?

Summary

How does aTyr Pharma compare to NervGen Pharma?

Summary

How does aTyr Pharma compare to Korro Bio?

Summary

How does aTyr Pharma compare to Molecular Partners?

Summary

How does aTyr Pharma compare to ADC Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATYR vs. The Competition

aTyr Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

aTyr Pharma (ATYR) Competitors

ATYR vs. LUCD, NGEN, KRRO, MOLN, and ADCT

How does aTyr Pharma compare to Lucid Diagnostics?

Which has preferable earnings & valuation, LUCD or ATYR?

Does the media refer more to LUCD or ATYR?

Do insiders & institutionals have more ownership in LUCD or ATYR?

Is LUCD or ATYR more profitable?

Do analysts rate LUCD or ATYR?

Which has more volatility and risk, LUCD or ATYR?

Summary

How does aTyr Pharma compare to NervGen Pharma?

Do analysts prefer NGEN or ATYR?

Is NGEN or ATYR more profitable?

Which has stronger earnings & valuation, NGEN or ATYR?

Does the media prefer NGEN or ATYR?

Do institutionals & insiders hold more shares of NGEN or ATYR?

Summary

How does aTyr Pharma compare to Korro Bio?

Does the media prefer ATYR or KRRO?

Which has more risk & volatility, ATYR or KRRO?

Is ATYR or KRRO more profitable?

Which has preferable earnings & valuation, ATYR or KRRO?

Do institutionals & insiders have more ownership in ATYR or KRRO?

Do analysts recommend ATYR or KRRO?

Summary

How does aTyr Pharma compare to Molecular Partners?

Do analysts recommend ATYR or MOLN?

Which has more volatility and risk, ATYR or MOLN?

Is ATYR or MOLN more profitable?

Does the media refer more to ATYR or MOLN?

Which has stronger valuation & earnings, ATYR or MOLN?

Do insiders and institutionals have more ownership in ATYR or MOLN?

Summary

How does aTyr Pharma compare to ADC Therapeutics?

Do analysts rate ADCT or ATYR?

Is ADCT or ATYR more profitable?

Does the media favor ADCT or ATYR?

Do insiders & institutionals have more ownership in ADCT or ATYR?

Which has better earnings & valuation, ADCT or ATYR?

Which has more volatility and risk, ADCT or ATYR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATYR vs. The Competition

aTyr Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools